| [1] |
ARROYO V, MOREAU R, KAMATH PS, et al. Acute-on-chronic liver failure in cirrhosis[J]. Nat Rev Dis Primers, 2016, 2: 16041. DOI: 10.1038/nrdp.2016.41. |
| [2] |
ARROYO V, MOREAU R, JALAN R. Acute-on-chronic liver failure[J]. N Engl J Med, 2020, 382(22): 2137-2145. DOI: 10.1056/NEJMra1914900. |
| [3] |
FERNÁNDEZ J, ACEVEDO J, WIEST R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis[J]. Gut, 2018, 67(10): 1870-1880. DOI: 10.1136/gutjnl-2017-314240. |
| [4] |
BAJAJ JS, REDDY KR, O'LEARY JG, et al. Serum levels of metabolites produced by intestinal microbes and lipid moieties independently associated with acute-on-chronic liver failure and death in patients with cirrhosis[J]. Gastroenterology, 2020, 159(5): 1715-1730. e12. DOI: 10.1053/j.gastro.2020.07.019. |
| [5] |
|
| [6] |
ALBILLOS A, de GOTTARDI A, RESCIGNO M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577. DOI: 10.1016/j.jhep.2019.10.003. |
| [7] |
TREBICKA J, AMOROS A, PITARCH C, et al. Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis[J]. Front Immunol, 2019, 10: 476. DOI: 10.3389/fimmu.2019.00476. |
| [8] |
TREBICKA J, FERNANDEZ J, PAPP M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology[J]. J Hepatol, 2020, 73(4): 842-854. DOI: 10.1016/j.jhep.2020.06.013. |
| [9] |
MACDONALD S, ANDREOLA F, BACHTIGER P, et al. Cell death markers in patients with cirrhosis and acute decompensation[J]. Hepatology, 2018, 67(3): 989-1002. DOI: 10.1002/hep.29581. |
| [10] |
MUÑOZ L, BORRERO MJ, U'BEDA M, et al. Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis[J]. Hepatology, 2019, 70(3): 925-938. DOI: 10.1002/hep.30349. |
| [11] |
WANG L, FOUTS DE, STÄRKEL P, et al. Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation[J]. Cell Host Microbe, 2016, 19(2): 227-239. DOI: 10.1016/j.chom.2016.01.003. |
| [12] |
DUBINKINA VB, TYAKHT AV, ODINTSOVA VY, et al. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease[J]. Microbiome, 2017, 5(1): 141. DOI: 10.1186/s40168-017-0359-2. |
| [13] |
LLOPIS M, CASSARD AM, WRZOSEK L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease[J]. Gut, 2016, 65(5): 830-839. DOI: 10.1136/gutjnl-2015-310585. |
| [14] |
CHEN Y, GUO J, QIAN G, et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality[J]. J Gastroenterol Hepatol, 2015, 30(9): 1429-1437. DOI: 10.1111/jgh.12932. |
| [15] |
WANG K, ZHANG Z, MO ZS, et al. Gut microbiota as prognosis markers for patients with HBV-related acute-on-chronic liver failure[J]. Gut Microbes, 2021, 13(1): 1-15. DOI: 10.1080/19490976.2021.1921925. |
| [16] |
YAO X, YU H, FAN G, et al. Impact of the gut microbiome on the progression of hepatitis b virus related acute-on-chronic liver failure[J]. Front Cell Infect Microbiol, 2021, 11: 573923. DOI: 10.3389/fcimb.2021.573923. |
| [17] |
SOLÉ C, GUILLY S, da SILVA K, et al. Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis[J]. Gastroenterology, 2021, 160(1): 206-218. e13. DOI: 10.1053/j.gastro.2020.08.054. |
| [18] |
LLORENTE C, JEPSEN P, INAMINE T, et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus[J]. Nat Commun, 2017, 8(1): 837. DOI: 10.1038/s41467-017-00796-x. |
| [19] |
MOREAU R, ELKRIEF L, BUREAU C, et al. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis[J]. Gastroenterology, 2018, 155(6): 1816-1827. e9. DOI: 10.1053/j.gastro.2018.08.026. |
| [20] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024. |
| [21] |
KIMER N, PEDERSEN JS, TAVENIER J, et al. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial[J]. J Gastroenterol Hepatol, 2018, 33(1): 307-314. DOI: 10.1111/jgh.13852. |
| [22] |
ABRALDES JG, VILLANUEVA C, ARACIL C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis[J]. Gastroenterology, 2016, 150(5): 1160-1170. e3. DOI: 10.1053/j.gastro.2016.01.004. |
| [23] |
BAJAJ JS, KASSAM Z, FAGAN A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial[J]. Hepatology, 2017, 66(6): 1727-1738. DOI: 10.1002/hep.29306. |
| [24] |
BAJAJ JS, SALZMAN NH, ACHARYA C, et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial[J]. Hepatology, 2019, 70(5): 1690-1703. DOI: 10.1002/hep.30690. |
| [25] |
DEFILIPP Z, BLOOM PP, TORRES SOTO M, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant[J]. N Engl J Med, 2019, 381(21): 2043-2050. DOI: 10.1056/NEJMoa1910437. |
| [26] |
FUCHS CD, PAUMGARTNER G, MLITZ V, et al. Colesevelam attenuates cholestatic liver and bile duct injury in mdr2 -/- mice by modulating composition, signalling and excretion of faecal bile acids[J]. Gut, 2018, 67(9): 1683-1691. DOI: 10.1136/GUTJNL-2017-314553. |
| [27] |
BAJAJ JS, IDILMAN R, MABUDIAN L, et al. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort[J]. Hepatology, 2018, 68(1): 234-247. DOI: 10.1002/HEP.29791. |
DownLoad: